©DANIEL ROUSSELOT/Sanofi

Sanofi and Regeneron Provide Update on Kevzara® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients

Originally published on sanofi.com.

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone (placebo).

Minor positive trends were observed in the primary pre-specified analysis group (critical patients on Kevzara 400 mg who were mechanically ventilated at baseline) that did not reach statistical significance and these were countered by negative trends in a subgroup of critical patients who were not mechanically ventilated at baseline1. In the primary analysis group, adverse events were experienced by 80% of Kevzara patients and 77% of placebo patients. Serious adverse events that occurred in at least 3% of patients and more frequently among Kevzara patients were multi organ dysfunction syndrome (6% Kevzara, 5% placebo) and hypotension (4% Kevzara, 3% placebo).

Based on the results, the U.S.-based trial has been stopped, including in a second cohort of patients who received a higher dose of Kevzara (800 mg). Detailed results will be submitted to a peer-reviewed publication later this year.

The primary analysis group included 194 patients who were critically ill with COVID-19 and receiving mechanical ventilation at the time of enrolment. The primary endpoint assessed the percentage of patients who achieved at least a 1-point change from baseline on a 7-point scale, which consisted of 1) death; 2) hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4) hospitalized, requiring supplemental oxygen; 5) hospitalized, not requiring supplemental oxygen – requiring ongoing medical care (COVID-19 related or otherwise); 6) hospitalized, not requiring supplemental oxygen – no longer requires ongoing medical care; 7) discharged from hospital. A second cohort, which was partially recruited (n=27), compared Kevzara 800 mg versus placebo.

The Kevzara trial was designed after a small (n=21), single-arm study in China (Xu et al) among mostly severe, febrile hospitalized COVID-19 patients found elevated IL-6 levels and suggested that inhibiting this pathway with the IL-6 blocker tocilizumab rapidly reduced fever and improved oxygenation in severe patients, allowing for successful hospital discharge. The Phase 3 Kevzara trial was designed to evaluate this hypothesis in a large, placebo-controlled trial. The trial has been funded in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under OT number: HHSO100201700020C.

A separate Sanofi-led trial outside of the U.S. in hospitalized patients with severe and critical COVID-19 using a different dosing regimen is ongoing. The same Independent Data Monitoring Committee (IDMC) is overseeing both the Regeneron-led U.S. trial and the Sanofi-led trial outside of U.S., which has recommended that the trial outside of the U.S. continue. The companies expect to report results in Q3 2020.

1: Endpoints  that showed positive trends in patients on mechanical ventilation at baseline, and were countered by negative trends in patients who were not mechanically ventilated at baseline included: the proportion of patients with a 1-point improvement on day 22 (primary endpoint for mechanical ventilation group); the proportion of patients who died by day 29; and proportion of patients who recovered by day 22.

Latest News

New Jersey, Hair, Discrimination, discriminate

3 Powerful Career Advice Tips for Women in Tech

Working as a woman in tech can have its challenges, especially since the industry is still male-dominated.  Though women make up half (50%) of all U.S. workers in STEM occupations, according to research, however, Black and Hispanic workers continue to be underrepresented in the STEM workforce. Black professionals represent only…

California, board, corporate, directors

California Bill Would Mandate Racial Diversity on Corporate Boards

A recent California bill would mandate diversity in corporate boards for all companies headquartered within the state. The bill would ban all-white corporate boards and comes on the heels of a 2018 law that mandated women hold seats in all corporate boards. This racial diversity bill AB 979 defines “underrepresented…

AT&T Summer Camp

Originally published on ATT.com Welcome to AT&T Summer Camp For kids across the country, summer camp is something to look forward to all year long. It’s a time when they connect with friends, try new things, discover untapped talents and grow as individuals. This summer, we’re reimagining the summer camp…

Southern Company: Low-Income Natural Gas Customers to Receive $1 Million in Energy Assistance Support from Atlanta Gas Light

Originally published on southerncompany.com. Under a mechanism created by the Georgia Public Service Commission last year, Atlanta Gas Light is allocating $1 million for supplemental low-income energy assistance, which will be distributed to qualifying agencies that support customers who need help paying natural gas bills, repairing or replacing natural gas appliances…